BRAF and colorectal carcinoma: Despite prescreening for BRAF V600E, MLH1 promoter hypermethylation was found in most of the MLH1-deficient CRC cases, supporting a hybrid approach for excluding likely sporadic cancers through sequential methylation analysis and BRAF testing (39).